Smith & Nephew (SNN) Return on Equity (2016 - 2023)

Smith & Nephew (SNN) reported Return on Equity of 0.0% for Q4 2023, little changed on a YoY basis from 0.0% in Q4 2022, and up 58.84% quarter-over-quarter from 0.0% in Q4 2022.

Smith & Nephew (SNN) Return on Equity (2016 - 2023) Analysis & Trends

Smith & Nephew has reported Return on Equity for 5 years, with the latest figure at 0.0% in Q4 2023.

  • For the quarter ending Q4 2023, Return on Equity changed 0.0% year-over-year to 0.0%; the trailing twelve-month figure through Dec 2023 stood at 0.0% (changed 0.0% YoY), and the FY2025 full-year result was 0.0%, changed 0.0% from the prior year.
  • Return on Equity for Q4 2023 stood at 0.0%, up from 0.0% in the prior quarter.
  • The five-year high for Return on Equity was 0.0% in Q4 2023, with the low at 0.0% in Q4 2022.
  • Historically, Return on Equity has averaged 0.0% across 3 years, with a median of 0.0% in 2021.
  • The largest YoY upside for Return on Equity was 0 bps in 2022 against a maximum downside of 0 bps in 2022.
  • Smith & Nephew's Return on Equity stood at 0.0% in 2021, then tumbled by 31 bps to 0.0% in 2022, then soared by 59 bps to 0.0% in 2023.
  • The last three Return on Equity figures came in at 0.0% (Q4 2023), 0.0% (Q4 2022), and 0.0% (Q4 2021), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROE (Qtr)
1 Abbott Laboratories 154.42 Bn 147.76 Bn 6.27 Bn 0.00%
2 Stryker 118.12 Bn 115.25 Bn 3.81 Bn 0.00%
3 Medtronic 101.72 Bn 93.55 Bn 5.76 Bn 0.00%
4 Boston Scientific 67.19 Bn 65.98 Bn 3.61 Bn 0.00%
5 Edwards Lifesciences 50.69 Bn 47.02 Bn 1.29 Bn 0.00%
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn 0.00%
7 Dexcom 28.09 Bn 26.97 Bn 750.30 Mn 0.00%
8 GE HealthCare Technologies 28.08 Bn 26.02 Bn 1.98 Bn 0.00%
9 Steris 19.80 Bn 19.37 Bn 697.10 Mn -
10 Smith & Nephew 5.27 Bn 4.69 Bn - -

Historic Data

Download Data
DateValue
Dec 31, 2023 0.00%
Dec 31, 2022 0.00%
Dec 31, 2021 0.00%
Dec 31, 2017 0.00%
Dec 31, 2016 0.00%